The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2023 | Outcomes for patients with multiple myeloma who have had first-line monoclonal antibody exposure
Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, discusses a study exploring the outcomes of patients with multiple myeloma (MM) who relapse after quadruplet therapy with a monoclonal antibody followed by autologous stem cell transplantation (autoSCT). Early progression leads to poorer survival, while later progression shows improved outcomes but still shorter progression-free survival (PFS) compared to those without prior monoclonal antibody exposure. This underscores the importance of considering previous exposure and timely access to novel therapies. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Adaptive biotechnologies: Consultancy, Honoraria; Amgen: Consultancy, Honoraria, Research Funding; Genentech: Research Funding; AbbVie: Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; Pfizer: Consultancy, Honoraria; BMS: Consultancy, Honoraria, Research Funding.
